A5091964584- Eosinophilic Esophagitis
- IL-33, ST2, and ILC Pathways
- RNA modifications and cancer
- Lung Cancer Treatments and Mutations
- Cancer-related molecular mechanisms research
- Esophageal Cancer Research and Treatment
- Circular RNAs in diseases
- Cytokine Signaling Pathways and Interactions
Zhengzhou University
2023-2024
<p>Supplementary Figure S2 shows the ROC curve analysis of anti-FDX1 autoantibody in different clinical subgroups NSCLC versus NC.</p>
<p>Supplementary Figure S4 shows the mRNA expression level of FDX1 in LUAD and LUSC patients based on GEPIA database.</p>
<p>Supplementary Figure S1 shows the protein expression level of FDX1 in A549 and PC-9 cells by western blotting analysis.</p>
<div>AbstractBackground:<p>Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis affects prognosis lung cancer. In this study, we investigated whether anti-FDX1 autoantibody could novel biomarker detection non–small cell (NSCLC).</p>Methods:<p>A total 1,155 plasma samples were divided into verification validation groups. The expression...
<p>Supplementary Figure S3 shows the ROC curve analysis of anti-FDX1 autoantibody in different clinical subgroups NSCLC versus BPN</p>
Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis affects prognosis lung cancer. In this study, we investigated whether anti-FDX1 autoantibody could novel biomarker detection non-small cell (NSCLC).